Closed

Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program

Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program, Solicitation fe66d512d41448bb81e795cdc32fc134, issued by Federal (Texas offices).

Key facts

Issuing agency
Federal (Texas offices)
Solicitation number
fe66d512d41448bb81e795cdc32fc134
Type
Solicitation
Posted
Feb 10, 2026
Response deadline
Apr 2, 2026, 1:00 PM EDT
Place of performance
San Antonio, TX, 78230

Official description

The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P& T COMMITTEE MEETING: The following MAY 2026 drug classes/subclasses will be reviewed: a. Antihemophilic Agents - Non-Factor Agents ALHEMO PEN HEMLIBRA HYMPAVZI PEN QFITLIA b. Leukemia and Lymphoma - BCR-ABL-TKI BOSULIF DANZITEN ICLUSIG IMKELDI PHYRAGO SCEMBLIX SPRYCEL TASIGNA NILOTINIB TARTRATE The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9201. Pre-quotation teleconference is on February 11, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference.

Solicitation #HT9402-26-Q-9201. Issued by DEPT OF DEFENSE › DEFENSE HEALTH AGENCY (DHA) › DEFENSE HEALTH AGENCY (DHA). NAICS 325412. Product/Service Code 6505.

Respond to this bid

This solicitation is administered by the issuing agency through SAM.gov, the federal contracting system. The official documents, any addenda and updates, and the procurement officer’s contact information are all posted there, and bid submission happens there, not on SledAtlas.

The direct link to the source posting (documents, addenda, updates, and the procurement contact) is free with a SledAtlas account. Sign in or create a free account.